Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | TGM1 | P22735 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070436 | 0.87 | PDE4B (0.34) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1071024 | 0.80 | PDE4B (0.33) | PDE4BPDE4APDE4CPDE4DSTING1 | |
| SCHEMBL1072632 | 0.80 | SMN1; SMN2 (0.36) | PDE4B | |
| SCHEMBL2427449 | 0.79 | PIK3CD (0.38) | PDE4BF13A1TGM2TGM1 | |
| SCHEMBL8221384 | 0.78 | PDE4B (0.39) | PDE4BF13A1TGM2TGM1PDE4A | |
| SCHEMBL1274041 | 0.71 | ACACB (0.34) | — | |
| SCHEMBL1083353 | 0.70 | RAB9A (0.36) | — | |
| SCHEMBL1072471 | 0.70 | RAB9A (0.36) | — | |
| SCHEMBL3302407 | 0.70 | GPR119 (0.36) | — | |
| SCHEMBL3305629 | 0.69 | ADRB2 (0.35) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | PDE4B 3086/4885F13A1 741/4885TGM2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.